Condition: Non-Small Cell Lung Cancer · Lung Cancer (NSCLC) · Sponsor: University Hospital, Basel, Switzerland
Aim of the study is to investigate the efficacy and safety of adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) in patients with advanced pre-treated non-small cell lung cancer (NSCLC).
This description comes directly from the study's public registry record.
David König, Dr. med. · +41 61 265 5074 · david.koenig@usb.ch
Heinz Läubli, Prof. Dr. med. · +41 61 265 5074 · heinz.laeubli@usb.ch
Always discuss trial participation with your own doctor first.
| Department of Medical Oncology, University Hospital Basel | Basel, Canton of Basel-City, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06455917